MD-miniRNA could be a more accurate biomarker for prostate cancer screening compared with serum prostate-specific antigen level

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3541-3547

  Xue, Dong ^a   Zhou, Cui Xing ^a   Shi, Yun Bo ^b   Lu, Hao ^a   He, Xiao Zhou ^a  

^a SOOCHOW UNIVERSITY   (China)

^b CHANGZHOU INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Diagnosis; MD miniRNA; Plasma; Prostate cancer; Prostatic hyperplasia

Indexed keywords

MD MINIRNA; PROSTATE SPECIFIC ANTIGEN; RNA; TUMOR MARKER; UNCLASSIFIED DRUG; LONG UNTRANSLATED RNA; MD-MINIRNA, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; UPREGULATION; AGED; BIOSYNTHESIS; BLOOD; GENETICS; MIDDLE AGED; PROSTATE TUMOR;

AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RNA, LONG NONCODING;

EID: 84929957877     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2990-x     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
3. Peyromaure EM, Mao K, Sun Y, Xia S, Jiang N, Zhang S, et al. A comparative study of prostate cancer detection and management in China and in France. Can J Urol. 2009;16:4472–7.
4. Zeigler-Johnson CM, Rennert H, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB, et al. Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol. 2008;15:4056–64.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
6. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics. 2010;3:8.
7. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:8247–52.
8. Mazhar D, Waxman J. Early chemotherapy in prostate cancer. Nat Clin Pract Urol. 2008;5:486–93.
9. Wilkinson S, Chodak GW. Critical review of complementary therapies for prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:2199–210.
10. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of micrornas in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.
11. Zhang C, Wang C, Chen X, Yang C, Li K, Wang J, et al. Expression profile of micrornas in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem. 2010;56:1871–9.
12. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J cancer J Int Cancer. 2013;132:116–27.
13. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.
14. Srivastava A, Goldberger H, Dimtchev A, Marian C, Soldin O, Li X, et al. Circulatory mir-628-5p is downregulated in prostate cancer patients. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35:4867–73.
15. Brosnan CA, Voinnet O. The long and the short of noncoding RNAs. Curr Opin Cell Biol. 2009;21:416–25.
16. Zaratiegui M, Irvine DV, Martienssen RA. Noncoding RNAs and gene silencing. Cell. 2007;128:763–76.
17. Ender C, Krek A, Friedlander MR, Beitzinger M, Weinmann L, Chen W, et al. A human snoRNA with microRNA-like functions. Mol Cell. 2008;32:519–28.
18. Mattick JS. The functional genomics of noncoding RNA. Science. 2005;309:1527–8.
19. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. The transcriptional landscape of the mammalian genome. Science. 2005;309:1559–63.
20. Motamedi MR, Verdel A, Colmenares SU, Gerber SA, Gygi SP, Moazed D. Two RNAi complexes, rits and rdrc, physically interact and localize to noncoding centromeric RNAs. Cell. 2004;119:789–802.
21. Ramskold D, Wang ET, Burge CB, Sandberg R. An abundance of ubiquitously expressed genes revealed by tissue transcriptome sequence data. PLoS Comput Biol. 2009;5:e1000598.
22. Costa FF. Non-coding rnas: Meet thy masters. Bioessays News Rev Mol Cell Dev Biol. 2010;32:599–608.
23. Wright CM, Kirschner MB, Cheng YY, O’Byrne KJ, Gray SG, Schelch K, et al. Long noncoding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (mpm). PLoS One. 2013;8:e70940.
24. Li H, Yu B, Li J, Su L, Yan M, Zhu Z, et al. Overexpression of lncRNA h19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5:2318–29.
25. Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, pcgem1. DNA Cell Biol. 2006;25:135–41.
26. Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res. 2011;39:2119-2128.
27. Wang XS, Zhang Z, Wang HC, Cai JL, Xu QW, Li MQ, et al. Rapid identification of uca1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res an Off J Am Assoc Cancer Res. 2006;12:4851–8.
28. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA malat1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73:1180–9.
29. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
30. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. Eau guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–40.
31. The management of lower urinary tract symptoms in men. London, 2010
32. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, et al. Pcat-1, a long noncoding RNA, regulates brca2 and controls homologous recombination in cancer. Cancer Res. 2014;74:1651–60.
33. Gandini O, Santulli M, Cardillo MR, Stigliano A, Toscano V: Correspondence re: J. B. De kok et al., dd3, a very sensitive and specific marker to detect prostate tumors. Cancer res., 62: 2695–2698, 2002. Cancer research 2003;63:4747; author reply 4748–4749
34. De Marzo AM, Coffey DS, Nelson WG. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology. 1999;53:29–39. discussion 39–42.
35. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding rna hotair reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–6.
36. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human hox loci by noncoding RNAs. Cell. 2007;129:1311–23.
37. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies pcat-1, an unannotated lincrna implicated in disease progression. Nat Biotechnol. 2011;29:742–9.
38. Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet. 2010;19:R152–61.
39. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465:1033–8.
40. Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, et al. Long non-coding rna metastasis associated in lung adenocarcinoma transcript 1 derived minirna as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49:2949–59.
41. Bond CS, Fox AH. Paraspeckles: nuclear bodies built on long noncoding RNA. J Cell Biol. 2009;186:637–44.
42. Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y, et al. The oncofetal h19 rna connection: hypoxia, p53 and cancer. Biochim Biophys Acta. 1803;2010:443–51.
43. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al. The c-myc oncogene directly induces the h19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res. 2006;66:5330–7.
44. Berteaux N, Lottin S, Monte D, Pinte S, Quatannens B, Coll J, et al. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by e2f1. J Biol Chem. 2005;280:29625–36.
45. Fellig Y, Ariel I, Ohana P, Schachter P, Sinelnikov I, Birman T, et al. H19 expression in hepatic metastases from a range of human carcinomas. J Clin Pathol. 2005;58:1064–8.
46. Weiss M, Plass C, Gerhauser C. Role of lncRNAs in prostate cancer development and progression. Biol Chem. 2014;395:1275–90.